Fig. 5From: Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potencyArmanezumab inhibited the seeding activity of pathological tau. a Co-incubation with Armanezumab blocked seeding activity of brain lysate of tau (P301S)/Tg mice and significantly decreased the ability to induce the aggregation of RDΔK280-CFP/RD-YFP in transiently transfected HEK293 cellsBack to article page